What is SEngine Precision Medicine?
SEngine Precision Medicine is at the forefront of personalized oncology, offering advanced diagnostic services through its CLIA-certified PARIS Test. This innovative assay analyzes tumor samples to identify the most effective therapies from an extensive database of oncology drugs. By providing oncologists and patients with actionable treatment options for solid tumors, SEngine aims to enhance patient outcomes beyond the capabilities of traditional DNA sequencing. The company's approach is designed to deliver tailored solutions, positioning it as a key player in the precision medicine landscape.
How much funding has SEngine Precision Medicine raised?
SEngine Precision Medicine has raised a total of $15.3M across 3 funding rounds:
Series A
$5.1M
Debt
$150K
Series A
$10M
Series A (2019): $5.1M with participation from Bangarang Group
Debt (2020): $150K led by PPP
Series A (2022): $10M supported by Bangarang Group, Washington Research Foundation, Alethea Fulcrum Fund, and Vincere Capital Biotech
Key Investors in SEngine Precision Medicine
Bangarang Group
Bangarang Group is an investor that has participated in multiple funding rounds for SEngine Precision Medicine, indicating a sustained interest in the company's growth and technology.
Washington Research Foundation
The Washington Research Foundation is a key backer, likely focusing on supporting scientific innovation and the commercialization of groundbreaking research in the life sciences sector.
Alethea Fulcrum Fund
Alethea Fulcrum Fund's participation suggests a strategic investment aimed at advancing SEngine Precision Medicine's mission in precision oncology and personalized medicine.
What's next for SEngine Precision Medicine?
With a major enterprise-level funding context and a recent strategic investment, SEngine Precision Medicine is poised for significant expansion. This capital infusion is expected to fuel further development of its PARIS Test technology, broaden its market reach to more oncologists and patients, and potentially forge new partnerships with pharmaceutical companies for drug development and clinical trials. The company's focus on functional assays for personalized cancer therapy suggests a trajectory towards becoming a leading provider of actionable insights in the fight against cancer.
See full SEngine Precision Medicine company page
